Read + Share

Amedeo Smart

Independent Medical Education


Read + Share

Alexander M, Cheng Y, Lee SH, Passaro A, et al. Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-small cell lung cancer: Patient satisfaction and resource utilization results from the PALOMA-3 study. Eur J Cancer 2025;227:115624.
PMID: 40730077


Privacy Policy